MGB and Dana-Farber expand early cancer detection amid cost and value questions

Mass General Brigham and Dana-Farber are expanding early cancer-detection programs, including genetic testing and blood-based screenings, as they push prevention and early intervention even as the institutions’ looming split raises questions about value, cost, and patient anxiety; experts caution that not all tests are proven and the benefits must be weighed against potential harms in a growing multicancer-detection market.